BACKGROUND: Ventricular assist devices (VADs) improve survival and quality of life in patients with advanced heart failure, but their use is frequently complicated by infection. There are limited data on the microbiology and epidemiology of these infections. METHODS AND RESULTS: One hundred fifty patients scheduled for VAD implantation were enrolled (2006-2008) at 11 US cardiac centers and followed prospectively until transplantation, explantation for recovery, death, or for 1 year. Eighty-six patients (57%) received HeartMate II devices. Data were collected on potential preoperative, intraoperative, and postoperative risk factors for infection. Clinical, laboratory, and microbiological data were collected for suspected infections and evaluated by an infectious diseases specialist. Thirty-three patients (22%) developed 34 VAD-related infections with an incidence rate of 0.10 per 100 person-days (95% confidence interval, 0.073-0.142). The median time to infection was 68 days. The driveline was the most commonly infected site (n=28); 18 (64%) were associated with invasive disease. Staphylococci were the most common pathogen (47%), but pseudomonas or other Gram-negative bacteria caused 32% of infections. A history of depression and elevated baseline serum creatinine were independent predictors of VAD infection (adjusted hazard ratio=2.8 [P=0.007] and 1.7 [P=0.023], respectively). The HeartMate II was not associated with a decreased risk of infection. VAD infection increased 1-year mortality (adjusted hazard ratio=5.6; P<0.0001). CONCLUSIONS: This prospective, multicenter study demonstrates that infection frequently complicates VAD placement and is a continuing problem despite the use of newer, smaller devices. Depression and renal dysfunction may increase the risk of VAD infection. VAD infection is a serious consequence because it adversely affects patient survival. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01471795.
BACKGROUND: Ventricular assist devices (VADs) improve survival and quality of life in patients with advanced heart failure, but their use is frequently complicated by infection. There are limited data on the microbiology and epidemiology of these infections. METHODS AND RESULTS: One hundred fifty patients scheduled for VAD implantation were enrolled (2006-2008) at 11 US cardiac centers and followed prospectively until transplantation, explantation for recovery, death, or for 1 year. Eighty-six patients (57%) received HeartMate II devices. Data were collected on potential preoperative, intraoperative, and postoperative risk factors for infection. Clinical, laboratory, and microbiological data were collected for suspected infections and evaluated by an infectious diseases specialist. Thirty-three patients (22%) developed 34 VAD-related infections with an incidence rate of 0.10 per 100 person-days (95% confidence interval, 0.073-0.142). The median time to infection was 68 days. The driveline was the most commonly infected site (n=28); 18 (64%) were associated with invasive disease. Staphylococci were the most common pathogen (47%), but pseudomonas or other Gram-negative bacteria caused 32% of infections. A history of depression and elevated baseline serum creatinine were independent predictors of VAD infection (adjusted hazard ratio=2.8 [P=0.007] and 1.7 [P=0.023], respectively). The HeartMate II was not associated with a decreased risk of infection. VAD infection increased 1-year mortality (adjusted hazard ratio=5.6; P<0.0001). CONCLUSIONS: This prospective, multicenter study demonstrates that infection frequently complicates VAD placement and is a continuing problem despite the use of newer, smaller devices. Depression and renal dysfunction may increase the risk of VAD infection. VAD infection is a serious consequence because it adversely affects patient survival. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01471795.
Authors: E A Rose; A C Gelijns; A J Moskowitz; D F Heitjan; L W Stevenson; W Dembitsky; J W Long; D D Ascheim; A R Tierney; R G Levitan; J T Watson; P Meier; N S Ronan; P A Shapiro; R M Lazar; L W Miller; L Gupta; O H Frazier; P Desvigne-Nickens; M C Oz; V L Poirier Journal: N Engl J Med Date: 2001-11-15 Impact factor: 91.245
Authors: M C Deng; M Loebe; A El-Banayosy; E Gronda; P G Jansen; M Vigano; G M Wieselthaler; B Reichart; E Vitali; A Pavie; T Mesana; D Y Loisance; D R Wheeldon; P M Portner Journal: Circulation Date: 2001-01-16 Impact factor: 29.690
Authors: O H Frazier; E A Rose; M C Oz; W Dembitsky; P McCarthy; B Radovancevic; V L Poirier; K A Dasse Journal: J Thorac Cardiovasc Surg Date: 2001-12 Impact factor: 5.209
Authors: S M Gordon; S K Schmitt; M Jacobs; N M Smedira; M Goormastic; M K Banbury; M Yeager; J Serkey; K Hoercher; P M McCarthy Journal: Ann Thorac Surg Date: 2001-09 Impact factor: 4.330
Authors: William L Holman; Soon J Park; James W Long; Alan Weinberg; Lopa Gupta; Anita R Tierney; Robert M Adamson; John D Watson; Edward P Raines; Gregory S Couper; Francis D Pagani; Nelson A Burton; Leslie W Miller; Yoshifumi Naka Journal: J Heart Lung Transplant Date: 2004-12 Impact factor: 10.247
Authors: Merilda O Blanco-Guzman; Xiaowen Wang; Justin M Vader; Margaret A Olsen; Erik R Dubberke Journal: Clin Infect Dis Date: 2021-01-27 Impact factor: 9.079
Authors: Nesreen Z Alsmadi; Sarah J Shapiro; Christopher S Lewis; Vinit M Sheth; Trevor A Snyder; David W Schmidtke Journal: Biomicrofluidics Date: 2017-11-28 Impact factor: 2.800
Authors: Saul N Friedman; Maryam Mahmood; Jennifer R Geske; Muhammad Rizwan Sohail; Geoffrey B Johnson; John M Stulak; Ayse Tuba Kendi Journal: Am J Nucl Med Mol Imaging Date: 2020-12-15
Authors: Joshua R Woolley; Jeffrey J Teuteberg; Christian A Bermudez; Jay K Bhama; Kathleen L Lockard; Robert L Kormos; William R Wagner Journal: Artif Organs Date: 2013-10-29 Impact factor: 3.094